Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI

NCT05530668 | Completed

• 1 other identifier: 8588
• Study Type: observational
• Target: 13
• Locations: 1 country
• Sites: 1

Brief Summary

There are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with MAOIs. However, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine. Given the numerous interactions between MAOIs and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. This is despite the fact that MAOIs are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. The arrival of antidepressants that can be combined with MAOIs, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. For these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.

Conditions

Depression Anxiety Disorder

Keywords

Depression Disorder; Anxiety Disorder; intranasal esketamine; monoamine oxidase inhibitors (MAOIs); MAOIs; antidepressants; ketamine

Outcome Measures

Primary Outcomes (1)

• Number of adverse events for each patient

  Files analysed retrospectively from January 01, 2018 to March 31, 2022 will be examined

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Major subject.having been treated with intranasal esketamine between 01/01/2018 and 01/03/2022.

You may qualify if:

• Major subject.
• Having been treated with intranasal esketamine between 01/01/2018 and 01/03/2022.
• Not objecting to the reuse of their data for scientific research purposes.

You may not qualify if:

• \- Subject who has expressed opposition to the reuse of their data for scientific research purposes.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de physiologie - Explorations fonctionnelles - CHU de Strasbourg - France

Strasbourg, 67091, France

Location

Related Publications (1)

• Dormegny-Jeanjean LC, Lenoir S, Humbert I, Mainberger OAE, Lozere C, Meyer C, Geny B, Michel B, Foucher JR, de Crespin de Billy C. Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses. Pharmacopsychiatry. 2025 Nov;58(6):273-283. doi: 10.1055/a-2590-3469. Epub 2025 Jun 2.

  PMID: 40456292 DERIVED

MeSH Terms

Conditions

Anxiety Disorders

Condition Hierarchy (Ancestors)

Mental Disorders

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 2, 2022
• First Posted: September 7, 2022
• Study Start: April 11, 2022
• Primary Completion: September 11, 2022
• Study Completion: December 11, 2022
• Last Updated: November 13, 2023

Record last verified: 2023-11

Locations

FR (1)